# **Special Issue**

## **Multi-Drug Resistance**

## Message from the Guest Editor

Drug resistance is an unavoidable consequence of the use of drugs, which is a major challenge, notably in cancer and infection. Multi-drug resistance (MDR), which is characterized by cross-resistance to a wide variety of drugs with distinct structures and mechanisms of action, has emerged as a major threat to global public health security. Deciphering the multidisciplinary and interdisciplinary characteristics of MDR in cancer and infection allows the development of novel precision medicine treatment modalities that can overcome different and well-defined drug resistance mechanisms. This Special Issue aims to provide up-to-date research, reviews and commentary on the mechanisms of MDR in the treatment of cancer and infection, new diagnostic and therapeutic tools against multi-drug-resistant tumors or bacteria, as well as potential therapeutic strategies to overcome MDR.

### **Guest Editor**

Dr. Na Xie

West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China

## Deadline for manuscript submissions

closed (31 December 2023)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/146667

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

